Vioxx, the implosion of Merck, and aftershocks at the FDA.
Horton
Richard
R
The Lancet, London NW1 7BY, UK.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D017277:Drug Approval; D004345:Drug Industry; D004346:Drug Information Services; D006801:Humans; D007373:Interinstitutional Relations; D007783:Lactones / Q000009:adverse effects*; D012449:Safety; D013450:Sulfones / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib